https://sputnikglobe.com/20211109/us-to-boost-stockpile-of-new-drug-for-covid-19-to-31mln-doses-1090601379.html
US to Boost Stockpile of New Drug for COVID-19 to 3.1Mln Doses
US to Boost Stockpile of New Drug for COVID-19 to 3.1Mln Doses
Sputnik International
WASHINGTON (Sputnik) - The Biden administration will purchase an additional 1.4 million doses of molnupiravir, an oral antiviral medicine that prevents... 09.11.2021, Sputnik International
2021-11-09T17:36+0000
2021-11-09T17:36+0000
2021-11-09T17:36+0000
us
food and drug administration (fda)
covid-19
https://cdn1.img.sputnikglobe.com/img/104485/60/1044856071_0:120:1280:840_1920x0_80_0_0_59583c8b596d2019749ff50060e89da8.jpg
“With these exercised options, the US government has now committed to purchase a total of approximately 3.1 million courses of molnupiravir, for approximately $2.2 billion, between authorization and early 2022,” the companies said in a joint press release.Merck and Ridgeback previously applied to the Food and Drug Administration (FDA) for emergency use authorization (EUA), with clinical trials showing molnupiravir 90 percent effective in preventing hospitalization and death of vulnerable adults with mild-to-moderate COVID-19 infections.In addition to the extra purchase of 1.4 million doses, the US also has options to purchase another 2 million courses, with the contract contingent on the drug receiving EUA, the release said.An FDA advisory committee plans to take up the EUA application on November 30, according to the release.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
us, food and drug administration (fda), covid-19
us, food and drug administration (fda), covid-19
US to Boost Stockpile of New Drug for COVID-19 to 3.1Mln Doses
WASHINGTON (Sputnik) - The Biden administration will purchase an additional 1.4 million doses of molnupiravir, an oral antiviral medicine that prevents hospitalization by attacking the novel coronavirus in early states of the disease, developers Merck and Ridgeback Biotherapeutics said on Tuesday.
“With these exercised options, the US government has now committed to purchase a total of approximately 3.1 million courses of
molnupiravir, for approximately $2.2 billion, between authorization and early 2022,” the companies said in a joint press release.
Merck and Ridgeback previously applied to the Food and Drug Administration (FDA) for emergency use authorization (EUA), with clinical trials showing molnupiravir 90 percent effective in preventing hospitalization and death of vulnerable adults with mild-to-moderate COVID-19 infections.
In addition to the extra purchase of 1.4 million doses, the US also has options to purchase another 2 million courses, with the contract contingent on the drug receiving EUA, the release said.
An FDA advisory committee plans to take up the EUA application on November 30, according to the release.
